Identification of the EML4-ALK fusion gene, which is present in 5-7% of non-small cell lung cancer (NSCLC) cases, has significant implications for therapy selection. Presence of the EML4-ALK gene promotes tumor cell growth, and also indicates poor response to therapies that inhibit EGF receptor (EGFR) activity. In patients carrying the EML4-ALK fusion gene, specific anaplastic lymphoma kinase or ALK inhibitors like Crizotinib have shown promising results.
Diagnostic testing for ALK fusion genes is routine in panel testing for NSCLC. QuanDx’s EML4-ALK fusion gene detection kit provides a simple multiplex test to detect commonly found EML4-ALK subtypes, requiring minimal sample preparation while providing consistent, reliable results.
For Research Use Only. Not intended for use in diagnostic procedures.
Product coming soon.
|Fusion Variants||V1, V2, V3a/b/c, V4, V5a/b, V6a/b, V7, V8a/b/d, V10|
|Sample types||FFPE, frozen, and fresh lung cancer tissue|
|Reaction Volume||20 µl|
|Reaction time||2 hours|
|Internal control||GUSB as housekeeping gene|
|Instruments||Compatible with Bio-Rad CFX96, iCycler, ABI7500, Roche Lightcycler 480, Stratagene Mx3000P/Mx3005P, and other commonly used RT-qPCR instruments.|
EML4-ALK Fusion Gene Detection Kit
Please contact us for a quote or with any questions about our products.